OBR Daily Commentary

forumImage

Chemotherapy Payment Reform: Medicare Is Missing the Elephant in the Room

(Independent Institute/The Beacon blog [Oakland, CA]) Aug 3, 2016 - Last May I wrote about the uproar over Medicare’s proposed changes to how it will pay doctors who inject drugs at their offices. This largely concerns chemotherapy.

Read Article arrow

William McGivney, PhD (Posted: August 05, 2016)

quotesThis article was spot on in framing this issue. It describes the unintended consequences of the proposed CMS directive although most anyone who understands the differences between cancer treatment provided by community oncology versus the hospital outpatient setting already is aware that this could only raise overall costs. In oncology we engage in clinical trials before we change treatment standards. CMS should do the same before they try to make sweeping changes in the delivery of cancer care. Study first implement later is the only prudent approach.quotes

Add Comment 2 Comment
forumImage

After Negative PET, Drop Bleomycin in Hodgkin's Lymphoma

(Medscape Medical News) June 22, 2016 - A response-adapted approach to the treatment of patients with advanced Hodgkin's lymphoma de-escalates treatment after an early negative PET scan and intensifies treatment in those with a PET-positive scan — those with the highest risk for treatment failure.

Read Article arrow

William McGivney, PhD (Posted: June 26, 2016)

quotesThis study is a game changer in providing data that supports stopping bleomycin in patients who are PET negative after two cycles of ABVD. However the real game changer may be the results of the phase III trial of front line treatment for advanced-stage Hodgkin's disease comparing ABVD with Seattle Genetic's brentuximab vedotin plus AVD (ClinicalTrials.gov NCT01712490) expected in 2017. If a positive study, as per the editorial in this week's NEJM, it may result in a "new standard of care for the first time in nearly three decades.”quotes

Add Comment 1 Comment
forumImage

ASCO Value Framework Update

(ASCO) May 31, 2016 - The American Society of Clinical Oncology (ASCO) today published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials.

Read Article arrow

William McGivney, PhD (Posted: June 01, 2016)

quotesMuch needed and potentially invaluable. I know I speak for many oncologists who are looking forward to working with and testing this new tool.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...